Abstract
Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Current Signal Transduction Therapy
Title:Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis
Volume: 10 Issue: 1
Author(s): Ying Wu, Yi Yang, Haishan Wu, Beibei Zhang, Hui Tang, Jingping Zhao and Jindong Chen
Affiliation:
Keywords: Bone mineral density, depression, OMICS, osteoporosis, SSRIs.
Abstract: Osteoporosis was related with depression especially in patients treated with psychotropic medicine. Selective serotonin reuptake inhibitors (SSRIs), the first-line treatment of depression, could up-regulate the extracellular serotonin (5-HT) levels and affect the serotonin system in bone metabolism. 5-HT transporter(5-HTT) knockout results in bone mass decreased, architecture altered and mechanical properties impaired. Antidepressant-induced osteoporosis has direct and dose-dependent effects. Thus depression patients should evaluate skeletal system and receive antiosteoporotic treatments regularly, particularly during use of SSRI. But some reports have shown a dissociation of Major depressive disorder (MDD) and bone mineral density (BMD). The relationship between depression, BMD and bone metabolism remains elusive. Further studies will be tackled by ‘OMICS’ to understand possible mechanisms and develop new antidepressant for MDD.
Export Options
About this article
Cite this article as:
Wu Ying, Yang Yi, Wu Haishan, Zhang Beibei, Tang Hui, Zhao Jingping and Chen Jindong, Insight into the Physiopathologic Mechanism for the Coexistence of Depression and Osteoporosis, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311000100
DOI https://dx.doi.org/10.2174/1574362410666150311000100 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 EnzymesMolecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 Enzymes
Current Drug Metabolism Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression
Current Neuropharmacology Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research The Antinflammatory Effect of Alpha-MSH in Skin: A Promise for New Treatment Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy
Current Pharmacogenomics and Personalized Medicine Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Skeletal Effects of Gonadotropin-Releasing Hormone Antagonists: A Concise Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Gliogenesis and Glial Pathology in Depression
CNS & Neurological Disorders - Drug Targets Striving for a Fuller Characterization of the Cellular Neuropathology of Depression Subtypes
Current Psychiatry Reviews Pharmacogenetics of Alcohol and Alcohol Dependence Treatment
Current Pharmaceutical Design Targeting Signal Transduction Pathways in the Treatment of Mood Disorders: Recent Insights into the Relevance of the Wnt Pathway
CNS & Neurological Disorders - Drug Targets Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents